Organon & Co. Earnings Call Transcripts
Fiscal Year 2025
-
Revenue and adjusted EBITDA for 2025 were $6.2B and $1.9B, respectively, with biosimilars and new product launches offsetting headwinds from loss of exclusivity and policy changes. 2026 guidance is flat, with continued cost discipline, margin pressure, and deleveraging focus.
-
The conference covered the completion of an internal investigation, ongoing cost discipline, and a shift toward commercial focus. Nexplanon faces U.S. headwinds but grows internationally, while Vtama's access improves despite revised sales targets. Biosimilars and targeted acquisitions support growth and deleveraging.
-
Q3 2025 revenue reached $1.6B with a 32.3% adjusted EBITDA margin, but full-year guidance was lowered due to U.S. policy headwinds and respiratory declines. Remediation for improper Nexplanon sales practices is complete, and the JADA divestiture will support deleveraging.
-
Second quarter revenue was $1.6B, down 1% at constant currency, with strong adjusted EBITDA and robust free cash flow. Guidance for full-year revenue and margins was raised, driven by growth in fertility, biosimilars, and VTAMA, while capital allocation focused on debt reduction.
-
The meeting approved all board proposals, including director elections and executive compensation, while a shareholder proposal on director resignation guidelines was not adopted. Financial results showed 3% revenue growth in 2024, with strategic focus on cost reduction, debt management, and leadership in women's health.
-
Q1 2025 results met expectations with strong growth from Nexplanon and VTAMA. Guidance for revenue and margins is affirmed, with a focus on deleveraging and capital redeployment from dividends to debt reduction. Limited tariff exposure and ongoing restructuring support future growth.
-
Strong 2024 results set the stage for 2025, with NEXPLANON and VTAMA driving growth despite Atozet LOE headwinds. New product launches, restructuring, and disciplined capital allocation support margin stability and future expansion.
Fiscal Year 2024
-
2024 saw 3% constant currency revenue growth to $6.4B and margin expansion, with Nexplanon and Vtama as key drivers. 2025 guidance anticipates flat constant currency revenue, $200M in OpEx savings, and stable EBITDA margins despite Atozet LOE and FX headwinds.
-
Q3 2024 saw 5% constant currency revenue growth, strong performance in women's health and biosimilars, and the Dermavant acquisition adding VTAMA. Guidance for 2024 was raised, with continued margin discipline and robust free cash flow supporting future growth.
-
Q2 2024 saw 2% constant currency revenue growth to $1.6B, with strong performance in Women's Health and Biosimilars, and steady margins. Full-year guidance was narrowed, with volume growth expected to offset pricing and LOE headwinds in H2.
-
The meeting covered board elections, approval of executive compensation, and auditor ratification, with all proposals passing. Financial results showed revenue growth across all franchises, a strong focus on women's health, and continued commitment to dividends and strategic investments.